Vabicaserin or placebo for acute schizophrenia symptoms
About this title
Read the official source — NCT00563706Researchers compared vabicaserin, risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared vabicaserin, risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 32 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 199
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00563706
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design Study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects With Acute Exacerbations of Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Little Rock, United States · Cerritos, United States · Escondido, United States
28 more locations
- Garden Grove, United States
- Glendale, United States
- San Diego, United States
- Torrance, United States
- Washington D.C., United States
- Aventura, United States
- Hollywood, United States
- Kissimmee, United States
- Hoffman Estates, United States
- Indianapolis, United States
- Lake Charles, United States
- Baltimore, United States
- Rockville, United States
- Hamilton, United States
- Willingboro, United States
- Cedarhurst, United States
- Holliswood, United States
- New York, United States
- Butner, United States
- Oklahoma City, United States
- Philadelphia, United States
- Austin, United States
- Bellaire, United States
- DeSoto, United States
- Houston, United States
- Arlington, United States
- Portsmouth, United States
- Kingston, Canada
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared vabicaserin, risperidone and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including vabicaserin and risperidone.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
